Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study

Aaron M. Praiss, Austin Miller, Judith Smith, Stuart M. Lichtman, Michael Bookman, Carol Aghajanian, Paul Sabbatini, Floor Backes, David E. Cohn, Peter Argenta, Michael Friedlander, Michael J. Goodheart, David G. Mutch, David M. Gershenson, Krishnansu S. Tewari, Robert M. Wenham, Andrea E. Wahner Hendrickson, Roger B. Lee, Heidi Gray, Angeles Alvarez SecordLinda Van Le, Roisin E. O'Cearbhaill

Research output: Contribution to journalArticlepeer-review


Objective: To determine the effects of using National Comprehensive Cancer Network (NCCN) guidelines to estimate renal function on carboplatin dosing and explore adverse effects associated with a more accurate estimation of lower creatinine clearance (CrCl). Methods: Retrospective data were obtained for 3830 of 4312 patients treated on GOG182 (NCT00011986)—a phase III trial of platinum-based chemotherapy for advanced-stage ovarian cancer. Carboplatin dose per patient on GOG182 was determined using the Jelliffe formula. We recalculated CrCl to determine dosing using Modification of Diet in Renal Disease (MDRD) and Cockcroft-Gault (with/without NCCN recommended modifications) formulas. Associations between baseline CrCl and toxicity were described using the area under the receiver operating characteristic curve (AUC). Sensitivity and positive predictive values described the model's ability to discriminate between subjects with/without the adverse event. Results: AUC statistics (range, 0.52–0.64) showed log(CrClJelliffe) was not a good predictor of grade ≥3 adverse events (anemia, thrombocytopenia, febrile neutropenia, auditory, renal, metabolic, neurologic). Of 3830 patients, 628 (16%) had CrCl <60 mL/min. Positive predictive values for adverse events ranged from 1.8%–15%. Using the Cockcroft-Gault, Cockcroft-Gault with NCCN modifications, and MDRD (instead of Jelliffe) formulas to estimate renal function resulted in a >10% decrease in carboplatin dosing in 16%, 32%, and 5.2% of patients, respectively, and a >10% increase in carboplatin dosing in 41%, 9.6% and 12% of patients, respectively. Conclusion: The formula used to estimate CrCl affects carboplatin dosing. Estimated CrCl <60 mL/min (by Jelliffe) did not accurately predict adverse events. Efforts continue to better predict renal function. Endorsing National Cancer Institute initiatives to broaden study eligibility, our data do not support a minimum threshold CrCl <60 mL/min as an exclusion criterion from clinical trials.

Original languageEnglish
Pages (from-to)213-223
Number of pages11
JournalGynecologic oncology
StatePublished - Jul 2023


  • Carboplatin dosing
  • Cockcroft-Gault formula
  • Creatinine clearance
  • Jelliffe formula
  • Modification of diet in renal disease formula
  • Wright formula


Dive into the research topics of 'Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study'. Together they form a unique fingerprint.

Cite this